Prokaryotic expression, purification, and polyclonal antibody production against a novel drug resistance gene of Leishmania donovani clinical isolate.
Diseases produced by protozoan parasites are one of the main causes of morbidity and mortality around the world, affecting millions of people. Among these, leishmaniasis has become the second most common cause of death and the problem is further complicated by the expansion of parasite resistance to the conventional drugs. The high rate of therapeutic failure thus calls for new rational approaches to develop alternative drugs. Understanding resistance mechanisms may help identify new targets for drug development. So we present here the cloning, expression, purification, and antibody production of a gene implicated in imparting resistance to pentavalent antimony (SbV) in clinical isolates of kala azar with a view to gain insight into the novel mechanism of its drug resistance.
Kothari
Hema
H
Drug Target Discovery and Development Division, Central Drug Research Institute, Lucknow, India.
Kumar
Pranav
P
Singh
Neeloo
N
D000818:Animals; D000906:Antibodies / Q000737:chemistry* / Q000302:isolation & purification; D000918:Antibody Specificity; D000965:Antimony / Q000494:pharmacology; D015153:Blotting, Western; D003001:Cloning, Molecular; D004351:Drug Resistance / Q000235:genetics*; D005786:Gene Expression Regulation / Q000187:drug effects; D017125:Genes, Protozoan / Q000235:genetics*; D007893:Leishmania donovani / Q000187:drug effects / Q000235:genetics*; D015800:Protozoan Proteins / Q000235:genetics* / Q000276:immunology / Q000302:isolation & purification*; D011994:Recombinant Proteins / Q000235:genetics / Q000276:immunology / Q000302:isolation & purification
D000906:Antibodies; D015800:Protozoan Proteins; D011994:Recombinant Proteins; D000965:Antimony